StemCell Therapy

New Clients: Get your pets first exam free. Pet Care Center of Apopka is located at 2807 North Rock springs Road, near Rock Springs Elementary. Pictured above are owners Dr. Kent Greer and wife Annie on their Apopka family farm.

More than 40 years ago Dr. Kent Greer, Hospital Director and founder of Pet Care Center of Apopka, graduated from University of Missouri.

Drawing on the example of his fathers practice, he opened his first veterinary hospital in 1985. Dr. Greer, a second-generation veterinarian, decided to build what was to become a new concept in veterinary hospitals for Central Florida. This facility offered in-house diagnostics with the very first IDEXX blood machines in the United States. Annie came on board as an animal behaviorist, and Annie and Dr. Greer married in 1996.

Dr. Greer is the senior doctor and oversees all aspects of his practice. Having over 40 years of surgical experience, including orthopedics and soft tissue and internal surgeries, hes a certified Veterinary Chiro-practitioner and has a profound interest in alternative medicine as a means to support conventional care. As such, he is one of the leaders in Central Florida of alternative therapies.

The skilled team at Pet Care Center of Apopka work to prevent and treat conditions as well as educate pet parents on all aspects of their pets health. To further extend their care, your pets first exam is free. This free first exam is a great time for them to get to know you and your pet, make preventive recommendations, and/or begin the path towards better health for your pet.

Sometimes, all your pet needs is a good look over with nutritional, behavioral, or exercise advice. Frequently, the staff at Pet Care Center of Apopka is referred to for second opinions. When a patient is experiencing ongoing health problems, they identify the cause and, in turn, make treatment recommendations. Your pet may be due for such things as vaccinations, a comprehensive veterinary examination that addresses the entirety of your pets well-being.

In 2003, Dr. Greer and his wife Annie saw a unique opportunity to expand their services. They created an exceptional, first-class pet resort, which is combined with their advanced medical services. They converted a family residence and added a $1.5-million state-ofthe-art boarding facility that retained the integrity of the beautiful six acres of woodland and grasslands on the property. Then they added a 35 x 24 ft swimming pool especially designed for your pet and their safety.

In these times of Covid, all precautions have been taken. With the space granted, the public is still able to wait inside and have face-to-face conversations with the doctor and staff. There is no waiting in the parking lot in your car. Deep cleaning is a given, and all staff and clients have felt safe. We are essential workers, and you, as clients are also deemed essential according to Orange County edict, stated Annie.

We are seeing an influx of new clients (eligible for a free exam) and many second opinions and certainly the case load of surgeries that are non-elective have increased exponentially.

In todays corporate takeover of veterinary medicine, experienced veterinarians capable of handling cruciate ligament surgeries, soft palate reconstruction and other serious conditions are simply not available, and the specialty practices are very often prohibitively expensive. Dr. Greer is valued for his years of surgical experience, and he is always happy to explain in length the procedure your dog may, or may not, need.

Pet Care Center of Apopka is now on Instagram and Face Book for ease of questions and information. Follow them, but most importantly, visit their website at centralfloridavets.com for the latest offers and information.

Pet Care Center of Apopka and Pet Resort of Apopka are conveniently located at 2807 North Rock Springs Rd, near Rock Springs Elementary. Open for business six days a week! Call 407-884-8924 to make an appointment or to get details regarding your free first time exam.

Advertisement

Excerpt from:
Pet Care Center of Apopka is your other family doctor that provides exceptional care from head to tail | - Apopka Chief

For the more adventurous pet owner, there are many advantages to owning goats, including companionship, land management by grazing, and milk production. While companionship and grazing come naturally to these critters, potential owners interested in collecting dairy from their goats need to take into consideration additional factors to encourage lactation and ensure that their goats milk is safe for consumption.

Dr. Evelyn Mackay, a clinical assistant professor at the Texas A&M College of Veterinary Medicine & Biomedical Sciences, says that the production capacity of a dairy goat depends on their breed, management, and nutrition.

The most common dairy goat breeds are Nigerian dwarf goats, Alpines, Saanens, Nubians, LaManchas, and Toggenburgs; Nigerian dwarves are significantly smaller than the other breeds and may be preferred by hobby farmers who would like a smaller milk yield.

Since goats will only lactate after giving birth to a kid, the relationship between parent and offspring must also be taken into account. Depending on the goat and management conditions, dairy goats can produce milk for many months after giving birth.

If owners are letting the kids nurse, owners will have a smaller milk yield than if they weaned the kids and only milked the goat, Mackay said. Some full-sized, high-producing goats can produce over two gallons per day at some stages of lactation. A home dairy goat would likely produce less than a gallon per day, especially if she is nursing kids.

Regardless of the goats desired milk yield, Mackay recommends that owners allow for a dry period between milking a goat and it giving birth again.

In order to impregnate a dairy goat, owners may keep their own male goats for breeding or can rent one via a stud service.

Its easier to own a male goat, but they are smelly and sometimes poorly behaved, Mackay said. Some people will borrow or lease a male if they only have a few females to breed. Artificial insemination can be done but is expensive and is more labor- and time-intensive than in other species.

Typically, dairy goats should be milked, fed, and cared for twice daily. After a goat is milked, it is important that owners ensure the goat milk is safe for consumption.

Owners should absolutely pasteurize their milk, she said. Raw milk is not safe for human consumption and can transmit dangerous diseases to people, such as Q Fever, brucellosis, listeriosis, salmonellosis, and many others.

Although the benefits of owning a dairy goat are many, potential owners should be aware of the care requirements to keep their goat healthy and fit for milk production.

They require just as much attention as other livestock, and paying close attention to udder health and overall health of dairy goats is very important, Mackay said. They can get mastitis (inflammation or infection of the breast tissue) and other diseases related to pregnancy and lactation. Owners need to learn appropriate milking hygiene procedures and be prepared to seek veterinary attention for their dairy goats if they become ill.

Pet Talk is a service of the College of Veterinary Medicine & Biomedical Sciences, Texas A&M University. Stories can be viewed on the web at vetmed.tamu.edu/news/pet-talk. Suggestions for future topics may be directed to editor@cvm.tamu.edu.

View post:
Pet talk: Got milk? The ins and outs of dairy goat ownership - Marshall News Messenger

NOVI. MICH (WXYZ) MSU Tollgate provides non-formal learning for children, families, and adults, offering the unique opportunity to experience agriculture hands-on in an urban environment.

You and yours are invited to spend time exploring the MSU Tollgate barn and pastures virtually as you investigate veterinary science and animal medicine. You'll get to know an array of animals as you experience the care of our livestock up close and personal.

You can also explore the five freedoms, engage in STEM challenges, and learn about veterinary tools & technology. Interactive real time sessions with MSU Extension Animal Science educators, Tollgate Farm staff, and visiting vets complement investigations and activities. This is the next best thing to being on the farm! A list of upcoming events is posted below.

The cost is $40 first youth participant, $25 additional youth in family. To learn more, visit https://www.canr.msu.edu/tollgate/

MSU Tollgate Farm Summer Stewards Teen Leadership Programs ages 13-19 https://events.anr.msu.edu/tollgatestewardsteenleadershipprogram/ [events.anr.msu.edu]The Tollgate Camp Teen Steward (15-19 yrs) and Tollgate Steward-in-Training (13-14 yrs) positions are for teens interested in gaining experience working with campers in outdoor farm setting. This experience offers teens a chance for stewards to enrich, mentor, and lead campers while gaining valuable leadership and life skills. In a positive educational environment, teens experience the responsibilities associated with potential career paths before entering college.

MSU Tollgate Farm Summer Stewards Sustainability Leadership Institute ages 15-19 https://events.anr.msu.edu/2021MSUTollgateSSLI/ [events.anr.msu.edu]Scheduled for June 14-19, 2021, SSLI is a fun, adventurous six-day training and youth development summit incorporating a mentorship model, a multi-day outdoor wilderness team building adventure, leadership roles, career exploration, and a capstone sustainability action project, all with a focus on educating for sustainability. For those interested in reconnecting with nature and exploring career connections to sustainability, this is the leadership experience for you!

Virtual MSU Tollgate Farm HomeGrown Gardening Series for families and individuals, sponsored by Bordines https://events.anr.msu.edu/msutollgatehomegrowngardening/ [events.anr.msu.edu]February September 2021Are you interested in starting a vegetable garden for the first time or are you an experienced veggie gardener looking to explore new ideas? All levels of experience are welcome at this new series designed to encourage and support home vegetable gardeners! $10 per session for one household, $75 for all eight sessions. Preregistration required.

Second Saturdays, 10 amFeb. 13 - Home Vegetable Gardening 101March 13 - Seed-Starting for EveryoneApril 10 - Vegetable Gardening in Small SpacesMay 8 - Growing Fun with KidsJune 12 - Taking Growing to New HeightsJuly 10 - Season Extension for the Home GardenAug. 14 - Companion PlantingSept. 11 - Veggie Harvest and Storage

Virtual MSU Tollgate Farm Interactive Series for School Teachers and Their Students https://events.anr.msu.edu/TollgateGroupVirtualFarmSeries/ [events.anr.msu.edu]

Follow this link:
Exploring MSU Tollgate virtually is the next best thing to being on the farm - WXYZ

The use of cannabidiol (CBD), the major non-psychoactive compound in cannabis, is on the rise across the United States. Pregnant women in particular may view CBD as more natural than other remedies for concerns such as nausea and pain, but the consequences of use for the developing fetus are unknown.

In a new study published in the journal Clinical Epigenetics, researchers at the University of Minnesota used a rodent model to investigate the impact of CBD during development and uncovered effects on the brain and behavior. They found that CBD use during pregnancy may affect mood and cognition in offspring long after the exposure has ceased. The study is the first to examine the effects of maternal CBD exposure during pregnancy on adult offspring in mammals.

The research team, made up of scientists at the University of Minnesotas Department of Animal Science and College of Veterinary Medicine, began by using a human-relevant dose that is typical in adults purchasing CBD over the counter for a variety of ailments. Next, the team treated pregnant mice daily throughout pregnancy and lactation until the pups were weaned. The offspring were followed into adulthood without any additional CBD, at which time they were measured for persistent behavioral and molecular impacts of CBD.

Specifically, the team of scientists investigated rodent behavior and DNA methylation, an important mechanism known as an epigenetic mark in both rodents and humans that helps control the when, where, and how much of gene activity. CBDs effects on gene activity markers were examined in two brain regions important for memory, mood, and cognition.

Among the studys key findings:

Chronic maternal CBD treatment increased anxiety and improved memory performance in adult female offspring, while males were unaffected.

The effects of CBD during pregnancy persisted even though the offspring had no direct exposure as adults.

Maternal CBD treatment shifted gene regulatory marks (DNA methylation) at hundreds of genes in the brains of adult female offspring.

Genes affected by CBD were involved in the formation of new neurons and synapses, communication between neurons, and diseases like autism spectrum disorder, epilepsy and substance use disorder.

CBD use has exploded in recent years, yet we still dont have a clear picture of its impact on the brain, especially during development, said study director Christopher Faulk, an assistant professor in the College of Food, Agricultural and Natural Resource Sciences. We show here that use during pregnancy can permanently impact the resulting offspring in adulthood and potentially for the rest of their lives.

The effects we observed on memory and anxiety were in 12-week-old mouse offspring, a time that approximates human young adulthood, and is cause for concern, said study co-author and project lead Nicole Wanner, a post-doctoral fellow in the College of Veterinary Medicine. DNA methylation marks in the brain are largely set during fetal development, and the presence of CBD during that process appears to direct certain permanent changes. We were surprised at the extent that CBD linked gene pathways were associated with neurological disorders, and expect future work will be needed to understand how fetal exposure to CBD impacts long-term brain function and mental health.

According to Faulk and Wanner, gaining more insight into how CBD affects the developing brain will be important for future safety recommendations.

The researchers are continuing to draw the epigenetic map of gestational CBD exposure and its impact on youth and adults. In the future, they hope to expand behavioral studies to include measures of sociability and drug reward, which are important for diseases like autism spectrum disorder and substance use disorder, respectively. They also plan to repeat these measurements in adolescent offspring in order to determine whether abnormalities are already present at an earlier age or whether they develop later.

Original post:
Study: CBD use during pregnancy affects the brain, behavior in adulthood - Southernminn.com

Host of Invited guests government officials and fellow veterinarians at the opening ceremony

On Friday, January 29, 2021, Dominica became the only Caribbean country with a medical school that solely focuses on veterinary studies.

This, according to the President of the St Nicholas University School of Veterinary Studies, Golnaz Naderkhani, MD Ph.D., who spoke during the official opening ceremony at the schools current location on the corner of Hillsborough Street and Kings Lane in Roseau.

Dr. Naderkhani made known that unlike the other medical schools in the region that also provide veterinary medicine education as a side branch, her university is 100% percent focused and dedicated to providing training in that discipline.

St Nicholas university is the first and only academic institution of its kind in the Caribbean, she stated. We are an academic institution committed to providing quality education training.

She said the pillars of her university are quality education, student center training, accessibility and affordability, sustainability, being at the heart of the community, personal learning experience, heritage and tradition, and character and morality.

The Canadian doctor who moved to Dominica following the passage of Hurricane Maria, informed the audience that very soon, Dominica will be the first to boast of having a specialized veterinary hospital capable of providing world-class care, equipped with a radiologist, pathologist, internist, orthopedic surgeon, oncologist, as well as an agro medicine and critical care specialist.

Due to the ongoing Covid-19 pandemic, she explained that students from high-risk countries such as the United States, Canada, and other Caribbean islands were not allowed to begin this semester, but will join in September of this year. Therefore, only ten students -all females- will be part of the very first class of students on February 1.

Dr. Naderkhani emphasized that once the international students are allowed into the university, this will result in new opportunities for many Dominicans.

Minister of Education and Human Resource Development, Hon. Octavia Alfred, who also spoke at the opening ceremony, stated that the opening of the medical school is an important milestone for all stakeholders and this must be celebrated.

For the government and people of Dominica, this presents an avenue to assist our young people who may be seeking advancement in this field to acquire a degree at home while opening up new opportunities for economic activities due to the presence of the university here, she stated.

Alfred stressed that the success or failure of the school will hold important implications for the Government, and pledged their commitment to providing support to growing the institutions reputation so that it may attract a cadre of young professionals eager to increase their skills and knowledge through the acquisition of a sound education in Dominica.

According to her, We need more veterinarians here who can play an essential role in promoting animal welfare.

Adding his voice to the commendations, Former Chief Veterinary Officer Dr. Reginald Thomas noted that there will no longer be a need to import veterinarians into the country from other parts of the world.

He said that the journey to realizing the establishment of the university in Dominica, has not been an easy one and he thanked the President for her steadfastness in achieving this dream and for choosing Dominica.

Continued here:
Dominica opens first university in the region to offer only veterinary studies - Dominica News Online

There are plenty of reasons to want to shift away from eating meat: its better for the planet and certainly better for animals that would otherwise be eaten. But meat is still a big draw, both in the U.S. and increasingly in medium-income countries like China.

At the Tufts School of Engineering, a team of scientists led by Professor David Kaplan is exploring another avenue to feed this trendmeat grown directly from animal cells. It could be the start of an entirely new agricultural industryas humane and green as plant-based meat substitutes, but providing taste, texture, and nutrition that is even closer to the experience of eating real meat.

The technology is already familiar to cell biologistsgrowing and harvesting cells from a single sample of tissue from a live anesthetized animal, but doing it in ways that may help the cells transform into something similar to the muscle tissue people enjoy eating from beef, chicken, and fish, including shrimp and scallops.

Meat from animals contains connective tissue, vascular networks, fat, and other cell types, as well as blood, biological fluids, and a complex mix of proteins and sugars, all of which contribute to the unique taste and texture of the meat. Replicating that structure and content is the technical challenge that the Tufts team is working on using the tools of tissue engineering.

A variety of flavors and textures can be achieved by growing different types of cells together, like skeletal muscle, fat cells and fibroblasts (the most common type of cell in connective tissue), adding nutrients to the surrounding media (the soup in which the cells grow), or using genetic modification to add components that not only introduce flavors, but can modify color or even improve on the nutritional quality of natural meat.

Andrew Stout, a doctoral student in biomedical engineering, has explored adding myoglobin to the cell growth media, for example. Myoglobin, a natural component of muscle, is a protein that carries iron and oxygen, and is associated with the bloody flavor of meat. He found that its addition to the mix helps improve the color of the cell mass, and even enhanced the growth rate of the meat substitute.

Stout has also been working to enhance the nutritional content of cell-based meat. In a recent journal publication, he reported how he had modified muscle cells from cows by genetically adding enzymatic machinery to produce the antioxidants phytoene, lycopene, and beta-carotene, normally found in plants.

Think of it as a way to make cell-based meat more plant-like in the healthy nutritional components it offers. Adding beta-carotene, for example, could have protective effects against colorectal cancer, which tends to be more prevalent among those with a high intake of red meat. Another benefit of this type of metabolic engineering is that the antioxidants could improve the quality and shelf-life of the meat.

How far can they take this nutritional engineering? I think other nutrients would definitely work, said Stout. Thats one of the things that I am the most excited about. Putting plant genes into mammalian cells is pretty un-travelled scientific territory, and so theres a lot of space to explore other nutrients, flavor, and color compounds. In addition, he adds, the cell-based meat can be engineered as a therapeutic food.

Most cell-based approaches have emulated processed meat such as hamburger, sausage, and nuggets. Replicating the appearance and texture of whole cuts of meat, like steak, is a different kind of challenge.

Tissue engineering experts in the Kaplan lab bring a lot of experience to the task of aligning cells and creating fibers resembling real meat structure, using things like mechanical tension and micropatterned substrates to help align cells into fibers.

Natalie Rubio, a Ph.D. student in biomedical engineering, found that switching from cows to caterpillars as a source of cells can have some advantages. The muscle and fat stem cells originating from the eggs of the tobacco hornworma beefy little caterpillarcan be used to generate tissue that resembles other invertebrates that were used to eating, like shrimp and scallops.

A vast amount of knowledge has already developed around large scale invertebrate cell culture, since insect cells are widely used in the production of pharmaceuticals. Suspended in a liquid medium, they tend to grow to very high density and have simpler requirements for maintenance and growth. Yields could be greater and production costs lower than from mammalian cells.

But Rubio explains that there is a very important step remaining to transform a soup of cells into something resembling real meatproviding a scaffold to shape and orient the cells.

The scaffold is the backbone of the meatit provides structure and texture, said Rubio. If we did not have that support structure, the meat would just look like slime.

Rubio generates scaffolds from chitosana polymer found in a closely related form (chitin) in exoskeletons such as crab shells and fungi. Chitosan is a great material to make scaffolds from because it is edible, abundant, and inexpensive, she said.

Chitin can be isolated from fungi and easily converted to chitosan and then formed into films, fibers, or sponges to act as scaffolding for cell culture. Rubio grows insect muscle and fat cells on the chitosan scaffolds to generate small, structured meat constructs.

Kaplans lab has been a hub and catalyst for cellular agriculture research and development in the academic sector for many years, he said. That continues with an annual course for undergraduates on cellular agriculture, which is again being offered this spring semester.

Cell-based meat has not yet been commercialized, but the first cultured beef burger was produced by Maastricht University in 2013, and a number of start-up companies are now working to create new products to sell.

Alumni from our group have fanned out across the globe to help create the foundation of a nascent cell-based agricultural industry, Kaplan said. They include Laura Domigan, who is a principal investigator at University of Auckland; research scientist Amanda Baryshyan at Gloucester Marine Genomics Institute; Ryan Pandya, CEO of Perfect Day Foods; Viktor Maciag, head of tissue engineering at Mission Barns; and Robin Simsa, CEO of Legendary Vish.

Mike Silver can be reached at mike.silver@tufts.edu.

Follow this link:
Their Goal: Meat That's Better Than Meat | Tufts Now - Tufts Now

Vancouver, British Columbia, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Stem Cell Therapy Market Size to Reach USD 5,040 Million by 2028 | Rising Public-Private Investments and Developing Regulatory Framework for Stem Cell Therapeutics will be the Key Factor Driving the Industry Growth, States Emergen Research

The global stem cell therapy market size was valued at USD 342.7 Million in 2019 and is anticipated to reach USD 3,693.6 Million by 2027 at a CAGR of 36.2%, over the forecast period, according to most recent analysis by Emergen Research.

Growing prevalence of chronic diseases will drive the growth of the stem cell therapy market. Increased investment in research activities, development of advanced genetic techniques, and rise in public-private partnership will contribute to the growth of the stem cell therapy market.

Stem cells are used to improve health and manage disease. The growing popularity of regenerative medicine has encouraged the growth of stem cell therapy market. Regenerative medicines are used to replace, repair, and regenerate tissues affected by disease, injury, and aging process. Regenerative medicines are used in research to find a cure for diabetes, Parkinson's, and Alzheimer's disease.

Claim Your FREE Sample Copy with Table of content@ https://www.emergenresearch.com/request-sample-form/83

However, ethical concerns regarding embryonic stem cells and less developed research infrastructure will hinder the stem cell therapy market's growth.

Companies Profiled in Stem Cell Therapy Market Research Report:

Virgin Health Bank, Celgene Corporation, ReNeuron Group plc, Biovault Family, Precious Cells International Ltd., Mesoblast Ltd., Opexa Therapeutics, Inc., Caladrius, Neuralstem, Inc., and Pluristem.

Key Highlights of Report

Check Our Prices@ https://www.emergenresearch.com/select-license/83Emergen Research has segmented the global stem cell therapy market in terms of type, application, end-users, and region:

Click to access the Report Study, Read key highlights of the Report and Look at Projected Trends: https://www.emergenresearch.com/industry-report/stem-cell-therapy-market

Take a Look at our Related Reports:

AI-Enabled Medical Imaging Solutions Market By Product (Software, Hardware), By Workflow (Image Acquisition, Image Analysis, Reporting, and Communication), By Therapeutic Application (General Imaging, Specialty Imaging), By Deployment Mode, By Modality, and By Region, Forecasts to 2027

Patient Registry Software Market By Delivery, By Database, By Registry Type, By Function, By Software Type (Integrated, Standalone), By End-use (Government & Third-Party Administrators, Pharmaceutical Companies, Hospitals, Research Centers, Others), and By Region, Forecast to 2027

Operating Room Management Solutions Market By Solution Type (Data management and communication solutions, Operating room supply management solutions, Anesthesia information management solutions, Operating room scheduling solutions, Performance management solutions), By Mode of Deployment (Ob-premises, Cloud-based), By End-Use (Hospitals, Ambulatory surgical centers), and By Region

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: http://www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Facebook | LinkedIn | Twitter | Blogs

Read Full Press Release@ https://www.emergenresearch.com/press-release/global-stem-cell-therapy-market

The rest is here:
Stem Cell Therapy Market Size to Reach USD 5,040 Million by 2028 | Rising Public-Private Investments and Developing Regulatory Framework for Stem Cell...

SAN DIEGO (PRWEB) January 29, 2021

ProgenCell Stem Cell Therapies announced an updated stem cell therapy for anti aging or healthy aging protocol. A Comprehensive protocol developed by the more than 12 years of experience in the field of Regenerative Medicine and the most rigorous scientific protocols, and overseen by an Independent Review Board (IRB) composed by prominent figures in medicine and scientific research.

The Anti Aging Stem Cell Treatment Protocol is performed administering stem cells intravenously with a previous and strict regimen of multivitamins, minerals and hormones and a subsequent nutritional and vitamin support.

This updated protocol has been developed thanks to the information we have been able to compile, analyze and research, allowing us to determine the dosage of the vitamins. Hormones and nutrients administered according to each patients context, added Dr. Jorge Luis Gavio ProgenCells Medical Director. ProgenCells stem cell research center has an in-house laboratory and adjacent medical facility, which not only sets us apart as an institution, it also gives us the scientific platform to upgrade our protocols, he continued.

To date, ProgenCell Stem Cell Therapies has been offering stem cell therapy in Mexico successfully with a wide range of protocolos designed specifically for many conditions including Parkinsons Disease, Multiple Sclerosis, Retinitis Pigmentosa, and arthritis just to name a few.

Stem cell therapy for anti aging at ProgenCell Stem Cell Therapies is offered by board certified and fully licensed doctors, and every case is overseed by an Independent Review Board, with a scientific and Ethics Committee.

The treatments at ProgenCell Stem Cells comply with quality assurance standards that exceed those recommended by the FDA (Federal Drug Administration), and all protocols are registered and audited by COFEPRIS (the mexican government agency with jurisdiction).

The process of becoming a ProgenCell Patient for Anti Aging Stem Cell Therapy Protocol starts with a free virtual consultation with a Regenerative Medicine Scientific Liaison who will guide you through the process and establish a health route map. After the treatment is booked, a patient concierge works with each international patient on travel logistics, to live the full ProgenCel Experience.

For more information on stem cell therapy for anti aging and to obtain a free consultation, call (888) 443-6235 or visit http://www.progencell.com to learn more.

Share article on social media or email:

See the original post:
ProgenCell - Stem Cell Therapies offers an updated Stem Cell Therapy for Anti Aging Protocol - PR Web

Stem Cell Therapy Market is valued at USD 9.32 Billion in 2018 and expected to reach USD 16.51 Billion by 2025 with the CAGR of 8.5% over the forecast period.

Rising prevalence of chronic diseases, increasing spend on research & development and increasing collaboration between industry and academia driving the growth of stem cell therapy market.

Scope of Stem Cell Therapy Market-

Stem cells therapy also known as regenerative medicine therapy, stem-cell therapy is the use of stem cells to prevent or treat the condition or disease. Stem cell are the special type of cells those differentiated from other type of cell into two defining characteristics including the ability to differentiate into a specialized adult cell type and perpetual self-renewal. Under the appropriate conditions in the body or a laboratory stem cells are capable to build every tissue called daughter cells in the human body; hence these cells have great potential for future therapeutic uses in tissue regeneration and repair. Among stem cell pluripotent are the type of cell that can become any cell in the adult body, and multipotent type of cell are restricted to becoming a more limited population of cells.

Get Sample of This Report@ https://brandessenceresearch.com/requestSample/PostId/1246

The stem cell therapy has been used to treat people with conditions including leukemia and lymphoma, however this is the only form of stem-cell therapy which is widely practiced. Prochymal are another stem-cell therapy was conditionally approved in Canada in 2012 for the treatment of acute graft-vs-host disease in children those are not responding to steroids. Nevertheless, hematopoietic stem cell transplantation is the only established therapy using stem cells. This therapy involves the bone marrow transplantation.

Stem cell therapy market report is segmented based on type, therapeutic application, cell source and by regional & country level. Based upon type, stem cell therapy market is classified into allogeneic stem cell therapy market and autologous market.

Stem Cell Therapy Companies:

Stem cell therapy market report covers prominent players like,

Based upon therapeutic application, stem cell therapy market is classified into musculoskeletal disorders, wounds and injuries, cardiovascular diseases, surgeries, gastrointestinal diseases and other applications. Based upon cell source, stem cell therapy market is classified into adipose tissue-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, cord blood/embryonic stem cells and other cell sources

The regions covered in this stem cell therapy market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of stem cell therapy is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Stem Cell Therapy Market Segmentation

By Type

Allogeneic Stem Cell Therapy Market, By Application

Autologous Market, By Application

By Therapeutic Application

By Cell Source

Stem Cell Therapy Market Dynamics

Rising spend on research and development activities in the research institutes and biotech industries driving the growth of the stem cell therapy market during the forecast period. For instance, in January 2010, U. S. based Augusta University initiated Phase I clinical trial to evaluate the safety and effectiveness of a single, autologous cord blood stem infusion for treatment of cerebral palsy in children. The study is estimated to complete in July 2020. Additionally, increasing prevalence of chronic diseases creating the demand of stem cell therapy. For instance, as per the international diabetes federation, in 2019, around 463 million population across the world were living with diabetes; by 2045 it is expected to rise around 700 million. Among all 79% of population with diabetes were living in low- and middle-income countries. These all factors are fuelling the growth of market over the forecast period. On the other flip, probabilities of getting success is less in the therapeutics by stem cell may restrain the growth of market. Nevertheless, Advancement of technologies and government initiative to encourage research in stem cell therapy expected to create lucrative opportunity in stem cell therapy market over the forecast period.

Stem Cell Therapy Market Regional Analysis

North America is dominating the stem cell therapy market due increasing adoption rate of novel stem cell therapies fueling the growth of market in the region. Additionally, favorable government initiatives have encouraging the regional market growth. For instance, government of Canada has initiated Strategic Innovation Fund Program, in which gov will invests in research activities carried out for stem cell therapies. In addition, good reimbursing scheme in the region helping patient to spend more on health. Above mentioned factors are expected to drive the North America over the forecast period.

Full Research Report @ https://brandessenceresearch.com/healthcare/stem-cell-therapy-market-size

About us: Brandessence Market Research and Consulting Pvt. Ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals, and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations, and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact usat: +44-2038074155 ormail usatsales@brandessenceresearch.com

Website: https://brandessenceresearch.com/

Article: https://businessstatsnews.com

Blog: https://technologyindustrynews.com

Blog: https://marketstatsreport.com

Blog: https://industrywatchnews.com/

See original here:
Stem Cell Therapy Market 2021: Global Key Players, Trends, Share, Industry Size, Segmentation, Forecast To 2027 KSU | The Sentinel Newspaper - KSU |...

IRVINE, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Ernesto Salegio, PhD will join the Company as Vice President, Segment Leader Translational and Pre-Clinical Research as part of ClearPoints Biologics and Drug Delivery team on March 1, 2021. Dr. Salegio brings over 19 years of experience in translational neuroscience with direct pre-clinical central nervous system (CNS) expertise in the delivery of therapeutics to the brain and spinal cord, including over 16 years of gene therapy experience working with adeno-associated viral vectors (AAV).

ClearPoint Neuros Biologics and Drug Delivery team was established in 2020 to provide turn-key medical device innovation, therapy delivery development and clinical services customized for both pharmaceutical and academic partners working on gene and stem cell therapies to the brain. This team also offers comprehensive services to help its partners navigate existing regulatory guidance and stay abreast of anticipated changes to guidance that will inevitably come.

Our current and prospective partners working on gene and stem cell therapies have an enormous unmet need for pre-clinical support, commented Jeremy Stigall, Vice President, Biologics & Drug Delivery Development. Ernestos extensive pre-clinical expertise in the intraparenchymal administration of therapeutics under image-guidance, as well into cerebrospinal fluid (CSF), will allow ClearPoint to add crucial translational consulting services for our biologics partners. When we establish relationships with pharmaceutical partners well before the clinic, ClearPoint products and services can be incorporated throughout the entire development process, delivering consistent, predictable performance, and providing government agencies assurance that the navigation and delivery platform will remain constant from bench-to-bedside. We aim to become their comprehensive medical device partner, allowing them to focus on more traditional pharmaceutical challenges, while ClearPoint delivers state-of-the-art medical device and therapy delivery.

I am thrilled to become a member of the ClearPoint team, commented Dr. Salegio. After spending almost two decades focusing on translational research, image-guided delivery protocols, complex surgical procedures and in the development of CNS therapies, I am delighted to drive the expansion of ClearPoints capabilities. I am eager to leverage their current pre-clinical and clinical portfolio, as well as to their pipeline of innovative tools on the horizon, to provide customized solutions to current and future ClearPoint pharmaceutical partners.

About ClearPoint Neuro

ClearPoint Neuros mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Companys current product portfolio include deep-brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active clinical sites in the United States and the EU. The Companys SmartFlow cannula is being used in partnership or evaluation with 25 individual biologics and drug delivery companies in various stages from preclinical research to late-stage regulatory trials. To date, more than 4,000 cases have been performed and supported by the Companys field-based clinical specialist team which offers support and services for our partners. For more information, please visit http://www.clearpointneuro.com.

Forward-Looking Statements

Statements herein concerning the Companys plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to the impact of COVID-19 and the measures adopted to contain its spread; future revenues from sales of the Companys ClearPoint Neuro Navigation System products; the Companys ability to market, commercialize and achieve broader market acceptance for the Companys ClearPoint Neuro Navigation System products; and estimates regarding the sufficiency of the Companys cash resources. More detailed information on these and additional factors that could affect the Companys actual results are described in the Risk Factors section of the Companys Annual Report on Form 10-K for the year ended December 31, 2019, and the Companys Quarterly Report on Form 10-Q for the three months ended September 30, 2020, both of which have been filed with the Securities and Exchange Commission, and the Companys Annual Report on Form 10-K for the year ended December 31 2020, which the Company intends to file with the Securities and Exchange Commission on or before March 31, 2021.

Visit link:
ClearPoint Neuro, Inc. Announces Expansion of Pre-Clinical and Translational Development Team to Support Gene and Stem Cell Therapy Partners -...

Global Stem Cell Therapy for Diabetes and Related Conditions Market Report offers in-depth analysis of the industry size, share, major segments, and different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and challenges.

The research document on Stem Cell Therapy for Diabetes and Related Conditions market comprises of key trends that define the industry growth in terms of the regional landscape and competitive outlook. It highlights the limitations & restraints as well as the growth avenues impacting the overall market dynamics. Apart from this, the report provides with significant information regarding the effect of Coronavirus pandemic on the industry remuneration.

Request a sample Report of Stem Cell Therapy for Diabetes and Related Conditions Market at:https://www.marketstudyreport.com/request-a-sample/3159653?utm_source=algos&utm_medium=Pravin

Key insights from COVID-19 impact analysis:

An overview of the regional landscape:

Additional information from the Stem Cell Therapy for Diabetes and Related Conditions market report:

Ask for Discount on Stem Cell Therapy for Diabetes and Related Conditions Market Report at:https://www.marketstudyreport.com/check-for-discount/3159653?utm_source=algos&utm_medium=Pravin

Comprehensive assessment of all opportunities and risks in the Stem Cell Therapy for Diabetes and Related Conditions market.

This exclusive study addresses key questions for stakeholders in the Stem Cell Therapy for Diabetes and Related Conditions Market:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-stem-cell-therapy-for-diabetes-and-related-conditions-market-research-report-with-opportunities-and-strategies-to-boost-growth-covid-19-impact-and-recovery

Some of the Major Highlights of TOC covers:

Stem Cell Therapy for Diabetes and Related Conditions Regional Market Analysis

Stem Cell Therapy for Diabetes and Related Conditions Segment Market Analysis (by Type)

Stem Cell Therapy for Diabetes and Related Conditions Segment Market Analysis (by Application)

Stem Cell Therapy for Diabetes and Related Conditions Major Manufacturers Analysis

Read More Related Reports at: https://www.marketwatch.com/press-release/Latest-report-on-Hydrocephalus-Shunts-Market-size-with-growing-CAGR-of-72-by-2025-2021-01-25

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

More:
Stem Cell Therapy for Diabetes and Related Conditions Market Size |Incredible Possibilities and Growth Analysis and Forecast To 2025 - AlgosOnline

This report of the global , Stem Cell Therapy Market systematically focuses on various factors such as current and past situations, developments, noteworthy business skills, preferences, and player strategies directly chosen by key market players to ensure stable revenue generation and long-term stability. Sure probability. With this report, research analysts and industry experts also aim to provide ample light on additional essential determinants such as scrutiny review and assessment of opportunities for analysis, as well as the threats and challenges that continue to curb the growth spike in the Stem Cell Therapy Market. The report provides a useful overview highlighting various aspects that encourage conservative business decisions in the Stem Cell Therapys market.

The market scope segment provides revenue to the electronic equipment market, predicting significant growth and future of the market. Stem Cell Therapy Market separation breaks down the major sub-areas that make up the market. The weekly segmentation section provides the biological market size. The modest background explains the competitive nature of the market, the market dividends and the description of the major players. Significant financial transactions that have shaped the market over the past few years are recognized.

Request For Sample PDF @ https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=re

Various workable inputs on ongoing market competition, growing intensity and relevant details about new product and technology development are included in the Stem Cell Therapy Market report. Additional details on M&A, commercial agreements and technology enhancements are also incorporated in the report. This section of the report draws attention towards competition analysis of the highlighted players and prominent vendors. Each of the mentioned players company and business overview with details on revenue generation, objectives and profit margin have been duly addressed in the report to encourage thoughtful business decisions amongst market aspirants as well as established players alike.

The report provides ample light on several market components such as key trends, ongoing challenges, as well as barriers and threats that significantly limit the growth of the global Stem Cell Therapy Market. This carefully written research report takes into account all the dominant regional and country-specific developments in the global Stem Cell Therapy Market. This report mainly focuses on key developments in North and South America, Europe, APAC and MEA regions

Complete Summary with TOC Available @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=re

Global Stem Cell Therapy Market 2020-26: Competitive Landscape Analytical Review

Compilation of this latest research report drives readers to have ongoing market developments, including paralyzing business and industrial development in numerous ways, including unprecedented advances such as the COVID-19 outbreak. The report is structured to highlight effective clues to growth-oriented business decisions, enabling manufacturers and stakeholders in the Stem Cell Therapy Market to come up with growth-friendly strategies and tactics.

Stem Cell Therapy Market Segmentation

Type Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

Systematic Guide to Report Investment

The report presents market size dimensions based on value and volume estimationsThe report demonstrates details on major dynamic alterations initiating growth diversionsThe report illustrates a touchpoint description of emerging segments and lucrative regional growth spots

What to expect from the Stem Cell Therapy Market report

1. The report investigates and makes the best forecasts related to market size and value estimation.2. A thorough evaluation to investigate material source and downstream purchasing development is reflected in the report.3. This report aims to characterize and segment the Stem Cell Therapy Market as a whole for the best reader understanding.4. Detailed references to buyer needs, barrier analysis and opportunity assessment are also taking root.

Market Report Highlights:

Chapter1. Executive SummaryChapter2. Research MethodologyChapter3. Stem Cell Therapy Market OutlookChapter4. Global Stem Cell Therapy Market Overview, By TypeChapter5. Global Stem Cell Therapy Market Overview, By ApplicationChapter6. Global Stem Cell Therapy Market Overview, By RegionChapter7. Company Profiles

Ask our Expert if You Have a Query @: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=re

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 210-667-2421/ +91 9665341414

See more here:
Stem Cell Therapy Market 2021 Industry Size, Trends, Global Growth, Insights And Forecast Research Report 2026 NeighborWebSJ - NeighborWebSJ

A comprehensive research study on Animal Stem Cell Therapy market available at MarketStudyReport.com provides insights into the market size and growth trends of this industry over the forecast timeline. The study evaluates key aspects of Animal Stem Cell Therapy market in terms of the demand landscape, driving factors and growth strategies adopted by market players.

The Animal Stem Cell Therapy market is a cohesive study of the existing scenario of this business sphere and incorporates a crisp outline of its segmentation. The report includes fairly accurate forecasts of the market status over the forecast duration and enumerates market size statistics with respect to sales volume and valuation. The study also illustrates a gist of the top players operating in the business landscape of the Animal Stem Cell Therapy market, along with the geographical realms and growth prospects of every region, in a comprehensive manner.

Request a sample Report of Animal Stem Cell Therapy Market at:https://www.marketstudyreport.com/request-a-sample/2416760?utm_source=fractovia.org&utm_medium=Ram

A run-through of the competitive landscape:

Unleashing the geographical penetration:

A detailed overview of the Animal Stem Cell Therapy market segmentation:

Ask for Discount on Animal Stem Cell Therapy Market Report at:https://www.marketstudyreport.com/check-for-discount/2416760?utm_source=fractovia.org&utm_medium=Ram

The Animal Stem Cell Therapy market study covers noteworthy details regarding the factors influencing the industry, impact of technological progressions on the vertical, risks, as well as substitute related threats faced by market players. Furthermore, the report details about the transition in customer preferences and consumers needs in consort with the impact of the shifting trends of the environmental, economic, and political scenario on the Animal Stem Cell Therapy market.

For More Details On this Report: https://www.marketstudyreport.com/reports/global-animal-stem-cell-therapy-market-research-report-2020

Related Reports:

1. Global Circadian Rhythm Sleep Disorders Market Size, Status and Forecast 2021-2026Read More: https://www.marketstudyreport.com/reports/global-circadian-rhythm-sleep-disorders-market-size-status-and-forecast-2021-2026

2. Global Single-Cell Analysis Market Size, Status and Forecast 2021-2026Read More: https://www.marketstudyreport.com/reports/global-single-cell-analysis-market-size-status-and-forecast-2021-2026

Read More Reports On: https://www.marketwatch.com/press-release/dilated-cardiomyopathy-market-analysis-size-regional-outlook-competitive-strategies-and-forecasts-to-2025-2021-01-25

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Go here to see the original:
Animal Stem Cell Therapy Market to witness high growth in near future - Fractovia News

A few odds and ends from Day 2 of the X Games Aspen 2021 at Buttermilk.

Im a huge foodie. My dream job is to be a food connoisseur. Im not kidding. Im going to Stanford in the fall, so people are, What are you interested in? I always say molecular genetics, because I am interested in that. But my dream job is actually to be a food connoisseur. After I do well at a contest, I have to go out and have a real nice meal. We are in Aspen, so there is a great selection. Its all take-out, but Im sure the food will be great. Eileen Gu, X Games rookie who won two golds and a bronze at Buttermilk

On her first run back in the X Games superpipe on Saturday, snowboarder Chloe Kim took a fall and then took to Instagram to let her 668K followers know that she low key popped some ribs out on that first slam.

Kim wasnt about to let a few out of place ribs stop her. She ended up finishing the competition in first place to earn her sixth X Games gold medal in the pipe.

Swiss skier Andri Ragettli hit a triple-cork 1800 on his first run Saturday night off the big air jump; by his third run, he added another half-rotation to pull off the triple-cork 1980 and secure his first Aspen gold medal.

The trip-19, Ive never done it. It was my first try in a comp. That was really nice to land it perfect, he said. Ive practiced the triple-cork 18 once here in practice, and I knew if everything was going perfect I land those tricks and I go for the 19 and I landed it as well.

With postponement of two snowboard events Saturday to Sunday, the final days schedule is a full one and the broadcast schedule on a few outlets.

The postponeded events, mens slopestyle and womens big air, will be available live on @XGames Twitter, Facebook and YouTube, ESPN said in an update Saturday.

Best to start at XGames.com for information on how to watch in case things change again. But, be ready for Shaun Whites return to the superpipe Sunday night at 6:30 p.m. on ESPN.

Readers around Aspen and Snowmass Village make the Aspen Times work possible. Your financial contribution supports our efforts to deliver quality, locally relevant journalism.

Now more than ever, your support is critical to help us keep our community informed about the evolving coronavirus pandemic and the impact it is having locally. Every contribution, however large or small, will make a difference.

Each donation will be used exclusively for the development and creation of increased news coverage.

Read the original post:
X Games Aspen Day 2 tidbits: Eileen Gu dreams of gold and being a food connoisseur - Aspen Times

Plant breeders realized decades ago they might be able to introduce improved varieties more quickly and ensure the new genetically stacked benefits remained stable. Then came the question, how do we do that?

Who better to ask than the person overseeing all this gene stacking magic on a daily basis Diana Horvath. Horvath, president of the 2Blades Foundation and a molecular biologist and biochemist, said her organization began working on gene stacking in 2005, using genes in bacterium. This allows the researchers to manipulate genes already in the plant and re-arrange them as desired. The technology of using bacterium to access genes has been available to researchers for three decades.

All the genes that went into the Big Five gene stack came from nature. Some of them were already present in common wheat. We used wheat, rye, and Sharon goatgrass, said Horvath.

We took beneficial genes from these different sources and stuck them tightly together one, two, three, four, five right next to each other, and stuck that in. The process of stitching together five genes is newer technology. Previously, plant breeders were limited to stitching only two genes. Now they can stack up to seven different genes in some cases.

The tools of modern molecular genetics have allowed us an insight into DNA and how these traits are encoded. Once we understood through microbiology and bio-chemistry what the chemical nature was, then it became clear that the structure was the same in one plant to the next plant. Or even in people. We all use the same chemical structure.

Horvath said the team is working toward different combinations of genes to protect the plant. Pathogens continually change and attempt to invade the gene sequence to overcome the resistance. The role of research is to stay one step ahead of pathogens, and it does that by putting together different sets of genes.

The 2Blade team is using molecular science to develop resistant wheat varieties, which Horvath said is much faster than conventional plant breeding. Molecular plant breeders around the world now have more genes available, and they know how to build the stack, so this is moving a lot faster.

She said 2Blade is also working to introduce gene stacks to prevent stripe rust, which causes more economic loss, but not the catastrophic loss, associated with stem rust.

Lets look at each kind of gene as a lock on the door, a combination lock. If you have only one gene or one combination lock protecting a wheat plant from a certain pathogen, then the pathogen only has to break the code for that one gene, and the disease takes over.

If we have five genes in the stack and each gene has its own code, its own lock on the door, then the pathogen has to get the code to all five combination locks, all five protective genes.

We should be clear that Big Five is not intended for commercial release. Its like a lab rat, basically a gene manipulating tool for other wheat breeders to use. It was chosen for its usability in the lab or in the greenhouse. Its relatively easy for other scientists to work with Big Five. We make the trait available to public and commercial breeders. Then its up to them to create better strains.

From a farmers point of view, it means a wheat variety can be developed with resistance to a whole array of pests. And from wheat, gene stacking technology will transfer to other commercial crops.

Horvath said there are restrictions on their work, in the form of strict federal regulations on any research involving genetic modifications to a plant. Many people and organizations have concerns about GM crops. She said the role of 2Blade is to provide the technical piece and to have these solutions ready for the rest of the world.

There are a number of ways 2Blade technology gets into the mainstream, she added. The foundation often give the genetic material free of charge to government or university wheat breeding programs anywhere around the globe. The other path is to license the material to commercial seed companies.

Technically, the way these strains are produced, they are genetically modified organisms. The question is how will consumers react to these products.

The issue we focus on is not how we arrive at gene stack strains. The issue were trying to address is a very serious disease that can greatly impact global food security and global hunger.

Were able to provide a safe solution. We feel its imperative to advance these products. Its up to the rest of the world to decide when theyre ready to receive them.

Read the original here:
Dissecting Big Five: all genes present in nature, not the same plant - Western Producer

Getting old is a complex matter. Research has shown that gut microbes are one of the factors that can influence several aspects of human life, including aging. Elucidating how a specific microbial species contributes to longevity is quite challenging given the complexity and heterogeneity of the human gut environment.

To explore the influence of bacterial products on the aging process, researchers at Baylor College of Medicine and Rice University developed a method that uses light to directly control specific gene expression and metabolite production from bacteria residing in the gut of the laboratory worm Caenorhabditis elegans.

We used optogenetics, a method that combines light and genetically engineered light-sensitive proteins to regulate molecular events in a targeted manner in living cells or organisms, said co-corresponding author Dr. Meng Wang, Robert C. Fyfe Endowed Chair on Aging and professor of molecular and human genetics and the Huffington Center on Aging at Baylor.

In the current work, the team engineered E. coli bacteria to produce the pro-longevity compound colanic acid in response to green light and switch off its production in red light. They discovered that shining the green light on the transparent worms carrying the modified E. coli induced the bacteria to produce colanic acid, which protected the worms gut cells against stress-induced mitochondrial fragmentation. Mitochondria have been increasingly recognized as important players in the aging process.

When exposed to green light, worms carrying this E. coli strain also lived longer. The stronger the light, the longer the lifespan, said Wang, an investigator at Howard Hughes Medical Institute and member of Baylors Dan L Duncan Comprehensive Cancer Center. Optogenetics offers a direct way to manipulate gut bacterial metabolism in a temporally, quantitatively and spatially controlled manner and enhance host fitness.

For instance, this work suggests that we could engineer gut bacteria to secrete more colanic acid to combat age-related health issues, said co-corresponding author Dr. Jeffrey Tabor, associate professor of bioengineering and biosciences at Rice University. Researchers also can use this optogenetic method to unravel other mechanisms by which microbial metabolism drives host physiological changes and influences health and disease.

Read the complete report in the journal eLife.

Other contributors to this work include first author Lucas A. Hartsough, Mooncheol Park, Matthew V. Kotlajich, John Tyler Lazar, Bing Han, Chih-Chun J. Lin, Elena Musteata and Lauren Gambill. The authors are affiliated with one of more of the following institutions: Baylor College of Medicine, Rice University and Howard Hughes Medical Institute.

Funding for this project was provided by Human Health Services and National Institutes of Health grants (1R21NS099870-01, DP1DK113644 and R01AT009050), National Aeronautics and Space Administration (grant NSTRF NNX11AN39H), the John S. Dunn Foundation and the Welch Foundation.

By Ana Mara Rodrguez, Ph.D.

Original post:
Light-activated genes illuminate the role of gut microbes in longevity - Baylor College of Medicine News

Our genetic codes control not only which proteins our cells produce, but also to a great extent in what quantity. This ground-breaking discovery, applicable to all biological life, was recently made by systems biologists at Chalmers University of Technology, Sweden, using supercomputers and artificial intelligence. Their research, which could also shed new light on the mysteries of cancer, was recently published in the scientific journal Nature Communications.

DNA molecules contain instructions for cells for producing various proteins. This has been known since the middle of the last century when the double helix was identified as the information carrier of life.

But until now, the factor which determines what quantity of a certain protein will be produced has been unclear. Measurements have shown that a single cell can contain anything from a few molecules of a given protein, up to tens of thousands.

With this new research, our understanding of the mechanisms behind this process, known as gene expression, has taken a big step forward. The group of Chalmers scientists have shown that most of the information for quantity regulation is also embedded in the DNA code itself. They have demonstrated that this information can be read with the help of supercomputers and AI.

You could compare this to an orchestral score. The notes describe which pitches the different instruments should play. But the notes alone do not say much about how the music will sound, he explains.

Information for the tempo and dynamics of the music are also required, for example. But instead of written instructions such asallegroorfortein connection with the notation, the language of genetics spreads this information over large areas of the DNA molecule. Previously, we could read the notes, but not how the music should be played. Now we can do both, states Aleksej Zelezniak.

Another comparison could be that now we have found the grammar rules for the genetic language, where perhaps before we only knew the vocabulary.

What then is this grammar, which determines the quantity of gene expression? According to Aleksej Zelezniak, it takes the form of reoccurring patterns and combinations of the four notes of genetics the molecular building blocks designated A, C, G and T. These patterns and combinations are known as motifs.

The crucial factors are the relationships between these motifs how often they repeat and at exactly which positions in the DNA code they appear.

We discovered that this information is distributed over both the coding and non-coding parts of DNA meaning, it is also present in the areas that used to be referred to as junk DNA.

The researchers tested the method in seven different model organisms from yeast and bacteria to fruit flies, mice, and humans and found that the mechanism is the same. The discovery they have made is universal, valid for all biological life.

According to Aleksej Zelezniak, the discovery would have not been possible without access to state-of-the-art supercomputers and AI. The research group conducted huge computer simulations both at Chalmers University of Technology and other facilities in Sweden.

This tool allows us to look at thousands of positions at the same time, creating a kind of automated examination of DNA. This is essential for being able to identify patterns from such huge amounts of data.

Jan Zrimec, postdoctoral researcher in the Chalmers group and first author of the study, agrees, saying:

With previous technologies, researchers had to tell the system which motifs in the DNA code to search for. But thanks to AI, the system can now learn on its own, identifying different motifs and motif combinations relevant to gene expression.

He adds that the discovery is also due to the fact they were examining a much larger part of DNA in a single sweep than had previously been done.

The new knowledge could also make it possible to better understand how mutations can affect gene expression in the cell and therefore, eventually, how cancers arise and function. The applications which could most rapidly be significant for the wider public are in the pharmaceutical industry.

It is conceivable that this method could help improve the genetic modification of the microorganisms already used today as biological factories leading to faster and cheaper development and production of new drugs, he speculates.

Reference: Zrimec J, Brlin CS, Buric F, et al. Deep learning suggests that gene expression is encoded in all parts of a co-evolving interacting gene regulatory structure. Nat Commun. 2020;11(1):6141. doi:10.1038/s41467-020-19921-4.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

More:
Deep Learning Shows How Genetic Motifs Conduct the Music of Life - Technology Networks

LA JOLLA, Calif., Jan. 27, 2021 /PRNewswire/ --Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced Alice S. Huang, Ph.D. has been appointed to the Company's board of directors. Concurrently with her appointment to the Board, Dr. Huang was appointed to serve on the Compensation Committee.

"We are pleased to add Dr. Huang to the Regulus board. We believe her extensive scientific background will be of benefit to helping direct the Company's drug discovery and development programs," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.

Dr. Huang is currently Senior Faculty Associate of Biology and Biological Engineering at the California Institute of Technology having joined Caltech in July 1997. Previous to her tenure at Caltech she was Dean for Science and Professor of Biology at New York University, Professor of Microbiology and Molecular Genetics at Harvard Medical School and Director, Laboratories of Infectious Disease at Boston Children's Hospital. She also served as director of Virus-Host Interactions in Cancer for 15 years, a training program at Harvard funded by the National Cancer Institute. Dr. Huang has served on the Board of Trustees of the Keck Graduate Institute since 1998 and has previously served on the Board of Trustees of Waksman Foundation for Microbiology, the Rockefeller Foundation, Public Agenda, Johns Hopkins University, the Health Effects Institute, and the University of Massachusetts. Dr. Huang is serving on the advisory boards of the Institute for Basic Biomedical Sciences at Johns Hopkins University School of Medicine since 2008 as well as the Schlesinger Library at Radcliffe Institute since 2018. She has previously served on the advisory boards of the National Foundation for Infectious Diseases, the US Army Medical Research & Development Command and Food & Drug Administration. She has been a fellow of the American Association of Women in Science since 1978, American Academy of Microbiology since 1982, Academia Sinica in Taiwan since July 1990, and the American Association for the Advancement of Science since 2000, serving as its president from 2010 to 2011.

Dr. Huang received her B.A., M.A. and Ph.D. degrees from the Johns Hopkins University.

About Regulus

Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus maintains its corporate headquarters in La Jolla, CA.

SOURCE Regulus Therapeutics Inc.

Home

See the rest here:
Regulus Announces Addition to Board of Directors - PRNewswire

An ambitious proposal to create a resistance gene atlas as a resource for the international wheat community has been outlined in a new review.

The R gene atlas would be a free, online directory from which combinations of resistance (R) genes could be identified by breeders and researchers and bred into wheat varieties.

The aim is to provide durable molecular protection against wheats major pathogens including wheat rusts, blotch diseases, powdery mildew, and wheat blast.

We sat down with Amber Hafeez and Dr Brande Wulff to find out more.

First author of the review Amber Hafeez explains: We lose one fifth of wheat yield annually to pests and pathogens, adding up to 209 million tonnes worth $31 billion.

To minimise that loss and reduce reliance on chemical protection we need broad spectrum and durable genetic resistance. Our atlas would bring together cloned resistance genes and pathogen virulence information so that users can pool the best combinations of resistance genes to fit local conditions.

Genetic resistance is precious; it is a finite resource and pathogens can evolve to quickly overcome individual resistance genes. We need to use resistance in a way that doesnt squander individual genes by releasing them in a stacked or combined way so that they will be effective for a long time.

The idea builds upon a recent surge in genomic resources available to researchers in wheat, facilitated by advancements in sequencing technologies and bioinformatics.

In the past few years, researchers at the John Innes Centre and The Sainsbury Laboratory have rapidly identified and cloned resistance genes in wheat and its wild relatives using technologies such as AgRenSeq, MutRenSeq and MutChromSeq.

This makes it possible to clone disease resistance genes in wheat or one of its wild relatives much faster and much more cheaply. Suddenly what was before just a pipe dream is now a potential reality: we could clone most if not all of the resistance genes in wheat, says Dr Brande Wulff, another author of the review and group leader at the John Innes Centre.

Wheat R genes work by recognising corresponding molecules in the pathogen called effectors. By identifying the effectors present in pathogen and pest populations, combinations or stacks of R genes could be designed.

The gene atlas would be a free online portal containing this genetic information and enabling breeders to design gene stacks using computer modelling before starting their breeding in the field.

It would also enable users to design molecular markers that they could run on wheat populations to find out what resistance genes they already have in their breeding programme.

One of the big problems currently is that breeders dont always know whether their resistance is coming from a single gene or due to two or three different genes. If they bring in something exotic from a wild relative, for example, they need to know that it is going to complement what they already have in their breeding programme, explains Dr Wulff.

Our R gene atlas is like putting a little flag everywhere where there is a resistance gene, a little address tag and that would allow breeders to put their molecular net across the genome and see where all the R genes are. That would allow them to combine existing and new R genes in ways that would give strength in unity.

The proposal details how the molecular components R genes and effectors involved in disease resistance could be captured from both the host and pathogen. Whole genome sequencing would be carried out on diversity panels of wheat, its progenitors and domesticated and wild relatives.

Then, association genetics a method of seeking useful genetic variation could be used to look for correlations between the host genotype and disease resistance or susceptibility and the genes responsible for these traits could be identified.

To combat eight of wheats major diseases, the researchers calculate it would cost around $58.6 million for the sequencing of diversity panels of the pathogens and 10 hosts, as well as funding 75 scientists to carry out the work.

This, they suggest, could be funded by contributions of $2.9 million per G20 country over five years which is likely to be a worthwhile return when disease losses can be valued at around $31.2 billion dollars each year.

Compared to the scale of the problem in yield losses to pests and pathogens, this represents excellent value for money, says Amber Hafeez. Our costs include sequencing, bulking up the seed and performing all the pathology experiments you would need for all these eight major diseases that we list as priorities, as well as including the costs of bioinformaticians and management.

The idea of bringing together an international consortium also allows the project to draw upon existing expertise and resources.

A lot of the pieces of the puzzle already exist, the idea is to bring them together to make sure we dont duplicate efforts, says Dr Wulff.

We see it as a centrally coordinated model distributed around different countries, using existing capacity. For example, there is an institute in Denmark called the Global Rust Reference Centre which can receive and work with exotic isolates of rust in a contained environment. This would be an ideal partner for the proposed endeavour.

We spoke to lots of breeders in different parts of the world and asked them this question: What could we do to incentivise us to use the atlas, this finite resource, judiciously to make it last as long as possible, says Dr Wulff.

One way involves patenting novel genes from wild relative backgrounds as a means of controlling the way they are used.

Another method of exerting control would be through the recommended lists which growers choose varieties from. The committees releasing cultivars onto the lists would award extra points to varieties which are likely to offer more durable resistance.

The gene atlas is a route to bringing disease resistance from the lab to the field at speed and in sufficient quantity. For researchers and breeders of wheat the most widely grown crop in the world that can only be a good thing, says Amber Hafeez.

Amber Hafeezs PhD is funded by the Norwich Research Park Biosciences Doctoral Training Partnership.

Go here to see the original:
Atlas puts wheat resistance genes on the map 27th January 2021 - The John Innes Centre

If you asked Freda Miller 10 years ago if stem cells could be harnessed to repair brain injuries and disease, she would have said it was too early to tell.

Today, she describes the progress that she and other regenerative medicine experts have madein understanding what regulates populations of stem cells cells with the potential to turn into many different cell typesand the rapid advances those discoveries have driven.

The approaches were using allow us to find so much information on things we could only dream of before.

Miller, who is also a professor at the University of British Columbia, is leading a Medicine by Design-funded team with expertise in computational biology, neurobiology, bioengineering and stem cell biology that is investigating multiple strategies to recruit stem cells to promote self-repair in the brain and in muscle. If it succeeds, the research could improve treatments for diseases such as multiple sclerosis (MS) and cerebral palsy, as well as brain injury.

Millers team is one of 11 at U of T and its partner hospitals that are sharing nearly $21 million in funding from Medicine by Design over three years. Funded by a $114-million grant from the Canada First Research Excellence Fund, Medicine by Design is a strategic research initiative that is working at the convergence of engineering, medicine and science to catalyze transformative discoveries in regenerative medicine and accelerate them toward clinical impact.

This is the second round of large-scale, collaborative team projects that Medicine by Design has funded. The support builds on the progressmade in the first round of projects (2016-2019) and is spurring further innovation to push regenerative medicine forward. It alsoled to a 2017 publicationby many of the same researchers on Millers current project in Cell Reports that essentially provided a roadmap for how brain stem cells build the brain developmentally, and then persist to function in the adult brain.

Miller, a neuroscientist, has always been fascinated by the brain and neurons, the network of billions of nerve cells in the brain. Around 15 years ago, when she started to take an interest in the potential regenerative capabilities of stem cells, she began to wonder if she could use stem cells to treat brain injury or disease. Though too little was known about stem cells at the time, she knew that it was a question worth investigating. But she also realized that making and integrating new nerve cells, which are the working parts of brain circuits, would be a daunting task.

Even if you can convince the stem cells to make more neurons, those neurons then have to survive and they have to integrate into this really complex circuitry, says Miller. It just made sense to me that if were really going to test this idea of self-repair in the brain, we should go after something thats more achievable biologically.

So, Miller turned her attention to a substance called myelin, which covers nerves and allows nerve impulses to travel easily. In many nervous system diseases MS is a well-known example and brain injuries, damage to and loss of myelin is a main factor in debilitating symptoms. Thanks in part to the team project award from Medicine by Design, Miller leads a team that has a focus on recruiting stem cells to promote the generation of myelin.

Miller says repairing myelin, also called remyelination, will eventually help to better understand the effects of the target disease or injury, possibly even leading scientists to discover how to reverse it. Boosting myelin is a promising area of research, she adds, because its not an all-or-nothing situation.

Even a little bit of remyelination could have a big impact. You dont have to win the whole lottery; you dont have to have 100 per cent remyelination to have a measurable outcome.

The teams work is not limited to generating myelin to treat nervous system diseases or brain injury. They are also looking at how they could recruit stem cells to generate more muscle. They are specifically looking at muscular dystrophy, but Miller says the applications from that work can be used in other diseases or situations where damage to muscles has occurred, such as age-related disorders.

Millers team includes experts from diverse fields: Gary Bader, a professor at the Donnelly Centre for Cellular and Biomolecular Research and a computational biologist; bioengineers Alison McGuigan, a professor in the department of chemical engineering and applied chemistry in the Faculty of Applied Science & Engineering, and Penney Gilbert, an associate professor at the Institute of Biomedical Engineering; Sid Goyal, a professor at the department of physics in the Faculty of Arts & Science; ProfessorDavid Kaplan and Assistant ProfessorYun Li, both in the Temerty Faculty of Medicine and a senior scientist and a scientist, respectively, at SickKids; stem cell biologist Cindi Morshead, a professor and chair of the division of anatomy in the department of surgery in the Temerty Faculty of Medicine; and Peter Zandstra, a University Professor in the Faculty of Applied Science & Engineering and director of Michael Smith Laboratories at the University of British Columbia.

Miller says Medicine by Designs contribution in bringing teams like hers together is immeasurable.

There are tangible results you can measure like publications and other grants and clinical trials, Miller says. But there are a lot of intangible things Medicine by Design brings to the table like developing a culture of people from very diverse places and allowing them to do science together at a time when the biggest breakthroughs are going to be made by combining technological and biological approaches. Its hard to do that if youre on your own.

This large, interdisciplinary team effort combines data and computer modelling to look at individual stem cells in the brain and predict their behaviours. Through experimentation, they can then test if the cells behave the way they predicted, which Miller says they have had great success with. From there, the team casts a wide net, testing various ways to try to control cells behaviour with the end goal of convincing the stem cells to turn into cells that aid in healing and repair.

One approach they use is testing already approved pharmaceuticals to see if they have the desired effect on the stem cells behaviour. This approach has had success. In summer 2020, Morshead, Miller and their collaborators, led by Donald Mabbott, a SickKids senior scientist and professor in the department of psychology in the Faculty of Arts & Science, published a paper in Nature Medicine that showed that metformin, a common diabetes drug, has the potential to reverse brain injury in children who had had cranial radiation as a curative therapy for brain tumours.

Miller says that, to her knowledge, this is the first paper that demonstrates that this type of brain repair is possible in humans.

Go here to see the original:
Medicine by Design researchers focus on promoting self-repair of the brain - News@UofT